A major clinical trial has raised significant new questions regarding how physicians determine which patients should be prescribed statins to prevent heart attacks and strokes. The study, which evaluated the effectiveness of using heart scans to guide treatment decisions, found that this imaging-based approach produced the exact same observed rate of major cardiovascular events as traditional risk assessments, even though the scans resulted in far fewer recommendations to begin taking statins.
The findings, presented during a prominent Hot Line session at the ESC Congress 2026, also uncovered a striking and unexpected difference in how consistently patients followed their prescribed medication regimens. Individuals who were advised to use statins based on the detection of calcium buildup within their coronary arteries were substantially more likely to follow through with their treatment recommendations compared to those whose guidance relied on conventional risk scoring models.
Although the results strongly suggest that heart scans could assist physicians in making more targeted and selective treatment decisions, the clinical trial ultimately did not establish that the scan-based approach was fully as effective as conventional risk assessments. Researchers noted that additional, larger studies are urgently required to determine whether direct arterial imaging offers a superior strategy for the long-term prevention of cardiovascular disease worldwide.
Why Predicting Heart Disease Risk Remains a Challenge
Cardiovascular disease stubbornly persists as the leading cause of illness and death across the globe. Much of this staggering global health burden originates from atherosclerotic cardiovascular disease, commonly known as ASCVD. This dangerous condition develops progressively when fatty deposits, clinically referred to as plaque, accumulate inside the interior walls of arteries. This accumulation gradually restricts normal blood flow and significantly increases the overall risk of heart attacks and strokes. Coronary artery disease and ischemic stroke represent two of the most prevalent and major clinical manifestations of this underlying condition.
Medical science has identified several common risk factors that substantially increase the likelihood of developing ASCVD over a person’s lifetime. These well-documented factors include cigarette smoking, diabetes, high blood pressure, and elevated levels of blood cholesterol. In daily clinical practice, physicians routinely rely on these individual factors to estimate a person’s overall cardiovascular risk profile and to determine whether the administration of preventive medications, such as statins, is clinically appropriate.
Statins remain among the most widely prescribed and thoroughly studied treatments for lowering that cardiovascular risk. These powerful medications work by reducing cholesterol levels in the blood, particularly low-density lipoprotein cholesterol, which is frequently designated as LDL or bad cholesterol. By successfully lowering these lipid levels, statins help dramatically decrease the likelihood of serious and potentially life-threatening cardiovascular complications.
However, accurately identifying which specific patients stand to benefit the most from statin therapy remains a remarkably complex and persistent clinical challenge. Clinical experience shows that some individuals who eventually suffer a catastrophic heart attack do not appear to be at particularly high risk when evaluated using conventional screening methods and risk calculators.
"For far too many patients, the first symptom of ASCVD is a heart attack," explained Doctor Joseph B Muhlestein from the Intermountain Medical Center in Murray, USA, who served as the Principal Investigator of the CorCal Outcomes trial. "Statins have been shown to be highly effective in the prevention of ASCVD; however, there is a major gap in risk assessment, statin initiation, and statin persistence."
According to Doctor Muhlestein, many individuals who suffer their first cardiovascular event, particularly younger adults, would not previously have been classified as possessing enough overall cardiovascular risk to justify initiating statin treatment under standard guidelines. This notable limitation has prompted clinical researchers to investigate whether directly examining the physical state of the arteries might provide much more useful and actionable clinical information.
Can Heart Calcium Scans Improve Statin Decisions?
To address these diagnostic limitations, the CorCal Outcomes trial was specifically designed to investigate two fundamentally different approaches for determining which patients should be advised to begin statin therapy before they ever experience a primary cardiovascular event.
The first approach relied upon the pooled cohort equations, a widely utilized and conventional risk assessment tool that estimates a patient’s short- and long-term cardiovascular risk using traditional demographic and clinical factors, such as age, total cholesterol levels, blood pressure measurements, and smoking status.
The second experimental approach measured coronary artery calcium, commonly abbreviated as CAC, which provides a much more direct physical indication of plaque buildup in the muscular arteries supplying oxygen-rich blood directly to the heart muscle.
This specialized measurement is performed using a computed tomography, or CT, scan designed specifically to detect microscopic and macroscopic calcium deposits residing within the coronary arteries. Calcium frequently accumulates over time within developing atherosclerotic plaque, making it an exceptionally useful and reliable marker of underlying coronary artery disease, even in individuals who have not yet developed any outward physical symptoms or chest discomfort.
Unlike traditional risk calculators, which merely estimate the statistical likelihood of future cardiovascular problems based on broad personal characteristics and routine health measurements, coronary calcium scans provide concrete, physical evidence of active disease already present within the coronary arteries.
The research team set out to determine whether utilizing this direct imaging information to guide clinical statin recommendations could successfully improve overall cardiovascular outcomes over time compared to standard predictive formulas.
Nearly 5,800 Patients Put Both Methods to the Test
The rigorous clinical trial successfully enrolled 5,772 patients drawn from the Canyons and Desert regions of Intermountain Health Care in the United States. All participating individuals had no previously documented history of ASCVD or diabetes and had not received any prior statin therapy, ensuring a clean cohort for primary prevention analysis.
The average age of the study population stood at 64 years old, and women accounted for 51 percent of the total study population, providing a well-balanced demographic representation.
Eligible participants were randomly assigned in a one-to-one ratio to one of two distinct study groups. One group received statin treatment guidance calculated entirely from traditional cardiovascular risk scores, while the opposing group received treatment recommendations based solely on the results of their coronary calcium scans.
Both the participating patients and their treating physicians were fully informed of the specific treatment recommendations generated by the respective study protocols. However, to maintain real-world clinical validity, the ultimate decision regarding whether or not to actually begin taking statins remained entirely in the hands of the patients and their personal doctors.
Following this initial phase, the researchers diligently tracked major cardiovascular events, which the study defined as a composite endpoint including all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and arterial revascularization procedures.
This comprehensive combined clinical outcome encompassed death resulting from any cause, acute heart attacks, strokes, and necessary medical procedures performed to surgically or percutaneously restore healthy blood flow through severely narrowed or completely blocked arteries.
Heart Scans Led to Far Fewer Statin Recommendations
After tracking the patient cohort for an average follow-up duration of 4.2 years, the researchers discovered that major cardiovascular events occurred at the exact same observed rate across both study groups.
Specifically, a total of 2.7 percent of patients in each respective group experienced one of the serious clinical events included in the trial’s primary composite outcome. The estimated relative risk over the duration of the follow-up period was also nearly identical, reflected by a hazard ratio of 0.99, a 95 percent confidence interval ranging from 0.71 to 1.38, and a p-value of 0.045 for noninferiority testing.
Despite this numeric similarity in clinical events, the study did not formally establish that the two distinct preventative strategies were equally effective. Crucially, the trial failed to meet its predetermined statistical requirement necessary to definitively demonstrate that the coronary calcium scan approach was not meaningfully worse than conventional risk assessment methods.
A striking and notable difference quickly emerged, however, in the frequency with which patients were advised to begin taking statin therapy.
Participants who were evaluated using traditional risk scoring equations received clinical recommendations to start statin therapy more than three times as often as those whose treatment decisions were guided by coronary artery calcium measurements.
Despite this substantial difference in the sheer volume of treatment recommendations generated by the two methods, both groups ultimately experienced the exact same observed rate of major cardiovascular events throughout the entire follow-up period.
A Surprising Difference in Statin Adherence
Perhaps the most intriguing and unexpected finding of the entire trial involved whether patients actually followed through with their prescribed medical treatments after leaving the clinic.
Among the subset of participants who were officially advised to take statins, patients whose treatment recommendations were based on direct coronary calcium scans proved to be significantly more likely to adhere to their prescribed medication regimen compared to those assessed using traditional cardiovascular risk factors alone.
The observed difference in medication persistence was substantial, recording adherence rates of 62 percent versus 23 percent, respectively.
Expressed differently, patients who received statin recommendations grounded in visible, physical evidence of calcium buildup within their own coronary arteries were approximately 2.7 times as likely to faithfully follow their long-term medication regimen.
One prominent and logical hypothesis among investigators is that seeing concrete visual evidence of active disease residing within their own arteries provides patients with a much stronger psychological motivation to take preventive medication seriously. However, the trial design was not structured to definitively establish the underlying psychological or behavioral reasons why adherence differed so dramatically between the two study arms.
These unexpected findings raise the distinct possibility that coronary calcium scans could powerfully influence not only which specific patients receive initial statin recommendations from their physicians, but also whether those patients consistently maintain their medications over the long term.
What the Findings Mean for Heart Disease Prevention
Despite these potentially important behavioral and clinical differences, the research team heavily emphasized that the current trial could not firmly establish whether calcium scan-guided treatment provides a level of long-term cardiovascular protection truly comparable to traditional risk assessment strategies.
One primary limitation highlighted by the investigators was that fewer study participants actually experienced major cardiovascular events than the research team had originally anticipated during the planning phases. With a smaller total number of clinical events available for statistical analysis, the trial possessed less statistical power to determine whether a clinically meaningful difference genuinely existed between the two competing approaches.
"The power of the study to detect a difference was reduced by the lower-than-expected event rates and we did not demonstrate noninferiority between the groups," stated Doctor Muhlestein. He concluded by noting that the trial provided critical insights: "The study did provide important hypothesis-generating insights into the efficiency of statin initiation and adherence when decisions are based on CAC scoring. Taken together, our data could be used to plan an additional well-powered randomized trial comparing CAC with current risk factor-based algorithms."
These empirical findings are expected to assist clinical researchers in designing future, highly powered trials capable of definitively determining whether routine coronary calcium scans can successfully improve the overall efficiency of statin prescribing without compromising essential cardiovascular protection.
Current European clinical recommendations already recognize a potential and valuable role for these specialized diagnostic measurements. The 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias explicitly recommends considering increased coronary calcium scores, when readily available, as an additional and helpful factor in comprehensive cardiovascular risk assessment.
This updated clinical guidance applies particularly to individuals categorized at moderate cardiovascular risk, or to those whose estimated numerical risk falls closely near the established clinical threshold at which preventive statin medication would normally be recommended by healthcare providers.
For these specific borderline individuals, obtaining concrete evidence of physical calcium buildup may assist physicians in making much more informed and personalized clinical decisions during moments when the necessity of lifelong statin therapy remains uncertain.
The findings from the CorCal Outcomes trial successfully add new data to this ongoing medical discussion by demonstrating that advanced heart scans may also heavily influence how faithfully patients adhere to their prescribed medical treatments. Whether that distinct behavioral advantage ultimately translates into superior long-term cardiovascular outcomes remains an essential question that will require dedicated future research to resolve.
